CDC Recommends MenB Vaccination in Late Adolescence — Physician’s First Watch
CDC Recommends MenB Vaccination in Late Adolescence
By Cara Adler
The recent Advisory Committee on Immunization Practices (ACIP) recommendations on vaccination against serogroup B meningococcal (MenB) disease have been published in MMWR and, thus, are officially endorsed by the CDC.
The key points: Patients ages 16 to 23 may be vaccinated, with a preference for vaccination at ages 16 to 18; ACIP found insufficient evidence to recommend vaccinating all adolescents.
In the past year, the FDA granted accelerated approval to two MenB vaccines (Trumenba and Bexsero), in response to outbreaks of MenB disease at colleges. The vaccines are approved for patients aged 10 to 25 years. ACIP's preference for vaccination at age 16 to 18 is intended to "maximize the likelihood that protection would last into the highest age-related risk period."
Among ACIP's other recommendations for MenB vaccination:
The same vaccine should be used for all doses in the series (three doses for Trumenba, two for Bexsero).
MenB vaccine can be administered at the same time as other vaccines recommended for this age group, preferably at a different site.
Pregnant and lactating women should not be vaccinated unless they are at high risk.